KRAS and cancer: Increasing evidence has shown that oncogenic mutations such as KRAS mutations are capable of mediating crosstalk with the immune system via oncogenic signaling and can lead to immune escape mechanisms at different stages of the cancer-immunity cycle (Figure 2) (6, 7).